These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

92 related articles for article (PubMed ID: 2329110)

  • 1. Development of ciprofloxacin resistance in Brucella melitensis.
    al-Sibai MB; Qadri SM
    J Antimicrob Chemother; 1990 Feb; 25(2):302-3. PubMed ID: 2329110
    [No Abstract]   [Full Text] [Related]  

  • 2. In vitro antibacterial activity of tigecycline in comparison with doxycycline, ciprofloxacin and rifampicin against Brucella spp.
    Turan H; Arslan H; Azap OK; Serefhanoğlu K; Uncu H
    Int J Antimicrob Agents; 2007 Aug; 30(2):186-7. PubMed ID: 17462865
    [No Abstract]   [Full Text] [Related]  

  • 3. Relevance of in vitro antimicrobial susceptibility of Brucella melitensis to relapse rate in human brucellosis.
    Ariza J; Bosch J; Gudiol F; Liñares J; Viladrich PF; Martín R
    Antimicrob Agents Chemother; 1986 Dec; 30(6):958-60. PubMed ID: 3813520
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In-vitro activity of ciprofloxacin, ceftriaxone and five other antimicrobial agents against 95 strains of Brucella melitensis.
    Bosch J; Liñares J; López de Goicoechea MJ; Ariza J; Cisnal MC; Martin R
    J Antimicrob Chemother; 1986 Apr; 17(4):459-61. PubMed ID: 2940209
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Susceptibility of Mexican brucella isolates to moxifloxacin, ciprofloxacin and other antimicrobials used in the treatment of human brucellosis.
    López-Merino A; Contreras-Rodríguez A; Migranas-Ortiz R; Orrantia-Gradín R; Hernández-Oliva GM; Gutiérrez-Rubio AT; Cardeñosa O
    Scand J Infect Dis; 2004; 36(9):636-8. PubMed ID: 15370648
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rifampicin resistance in a strain of Brucella melitensis after treatment with doxycycline and rifampicin.
    De Rautlin de la Roy YM; Grignon B; Grollier G; Coindreau MF; Becq-Giraudon B
    J Antimicrob Chemother; 1986 Nov; 18(5):648-9. PubMed ID: 3804888
    [No Abstract]   [Full Text] [Related]  

  • 7. [Evolution of antibiotic sensitivity in Brucella melitensis].
    Pulido A; Liñares J; Escribano E; Alonso T; Ariza J
    Enferm Infecc Microbiol Clin; 1992 Jan; 10(1):56-7. PubMed ID: 1498179
    [No Abstract]   [Full Text] [Related]  

  • 8. Susceptibility of Brucella melitensis to fluoroquinolones.
    Qadri SM; Akhtar M; Ueno Y; al-Sibai MB
    Drugs Exp Clin Res; 1989; 15(10):483-5. PubMed ID: 2632216
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vitro antimicrobial susceptibility of Brucella species.
    Baykam N; Esener H; Ergönül O; Eren S; Celikbas AK; Dokuzoguz B
    Int J Antimicrob Agents; 2004 Apr; 23(4):405-7. PubMed ID: 15081093
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification of Brucella species isolated from proven brucellosis patients in Izmir, Turkey.
    Köse S; Kiliç S; Ozbel Y
    J Basic Microbiol; 2005; 45(4):323-7. PubMed ID: 16028204
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Failure of prolonged treatment with ciprofloxacin in acute infections due to Brucella melitensis.
    Lang R; Raz R; Sacks T; Shapiro M
    J Antimicrob Chemother; 1990 Dec; 26(6):841-6. PubMed ID: 2081722
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Implantable cardioverter-defibrillator infection due to Brucella melitensis: case report and review of brucellosis of cardiac devices.
    Dhand A; Ross JJ
    Clin Infect Dis; 2007 Feb; 44(4):e37-9. PubMed ID: 17243046
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Biotypes and antimicrobial susceptibilities of Brucella isolates.
    Bodur H; Balaban N; Aksaray S; Yetener V; Akinci E; Colpan A; Erbay A
    Scand J Infect Dis; 2003; 35(5):337-8. PubMed ID: 12875523
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Quinolones for brucellosis: treating old diseases with new drugs.
    Pappas G; Christou L; Akritidis N; Tsianos EV
    Clin Microbiol Infect; 2006 Sep; 12(9):823-5. PubMed ID: 16882286
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mutant prevention concentrations of tetracycline, rifampicin and ciprofloxacin for Brucellae melitensis.
    Coban AY; Tanyel E; Tasdelen Fisgin N; Darka O; Tulek N; Durupinar B
    J Chemother; 2007 Oct; 19(5):596-8. PubMed ID: 18073161
    [No Abstract]   [Full Text] [Related]  

  • 16. Failure of a short-term antibiotic therapy for human brucellosis using ciprofloxacin. A study on in vitro susceptibility of Brucella strains.
    Al Dahouk S; Hagen RM; Nockler K; Tomaso H; Wittig M; Scholz HC; Vergnaud G; Neubauer H
    Chemotherapy; 2005 Oct; 51(6):352-6. PubMed ID: 16227689
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Determination of in vitro susceptibilities of Brucella spp. strains against 11 different antibacterial gents isolated from blood cultures].
    Keşli R; Bilgin H; Yılmaz H
    Mikrobiyol Bul; 2017 Jul; 51(3):260-268. PubMed ID: 28929962
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [E-test susceptibility results of brucella strains for streptomycin, rifampicin, ciprofloxacin and tetracycline].
    Sengöz G; Yaşar KK; Kutlu SB; Durdu YB; Ozdemir R; Nazlican O
    Mikrobiyol Bul; 2006 Jul; 40(3):265-8. PubMed ID: 17001857
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Study on antimicrobial susceptibility of Brucella in a city].
    Zuo SW; Ni ZL; Yao YB; Yang RS; Wang SK; Zhou YH
    Zhonghua Lao Dong Wei Sheng Zhi Ye Bing Za Zhi; 2017 Dec; 35(12):939-941. PubMed ID: 29495161
    [No Abstract]   [Full Text] [Related]  

  • 20. In vitro antimicrobial susceptibility testing of human Brucella melitensis isolates from Ulanqab of Inner Mongolia, China.
    Liu ZG; Di DD; Wang M; Liu RH; Zhao HY; Piao DR; Zhao ZZ; Hao YQ; Du YN; Jiang H; Cui BY; Xia XZ
    BMC Infect Dis; 2018 Jan; 18(1):43. PubMed ID: 29338693
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.